endocrine, metabolic & immune disorders drug targets

[1] Brain Angiotensinergic Regulation of the Immune System: Implications for Cardiovascular and Neuroendocrine Responses.

[2] diabetes and hypertension, as well as obesity and alzheimer’s disease, are linked to hypohydration-induced lower brain volume

[3] antibodies to probe endogenous g protein-coupled receptor heteromer expression, regulation and function.

[4] Angiotensin II type 2 receptor blocker PD123319 has more beneficial effects than losartan on ischemia/reperfusion injury and oxidative damage in isolated rat heart.

[5] Effects of voluntary exercise on blood pressure, angiotensin II, aldosterone, and renal function in two-kidney, one-clip hypertensive rats

[6] Chronic resveratrol reverses a mild angiotensin II-induced pressor effect in a rat model

[7] Effects of antihypertensive drugs on carotid intima-media thickness: Focus on angiotensin II receptor blockers. A review of randomized, controlled trials

[8] Critical review of cancer risk associated with angiotensin receptor blocker therapy

[9] Effects of voluntary exercise on blood pressure, angiotensin II, aldosterone, and renal function in two-kidney, one-clip hypertensive rats

[10] Chronic resveratrol reverses a mild angiotensin II-induced pressor effect in a rat model

[11] Effects of antihypertensive drugs on carotid intima-media thickness: Focus on angiotensin II receptor blockers. A review of randomized, controlled trials

[12] Critical review of cancer risk associated with angiotensin receptor blocker therapy

[13] Angiotensin receptor blockers & endothelial dysfunction: Possible correlation & therapeutic implications

[14] Data supporting the angiotensin II activates MEL18 to deSUMOylate HSF2 for hypertension-related heart failure

[15] Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?

[16] Angiotensin Receptor Blockers Effect on Serum Uric Acid-A Class Effect?

[17] Effects of angiotensin-II on brain endothelial cell permeability via PPARalpha regulation of para- and trans-cellular pathways.

[18] Roles of I in the downregulation of eNOS Ser1177 phosphorylation by angiotensin II-activated PP2A.

[19] Proactive treatment of angiotensin receptor antibodies in kidney transplantation with plasma exchange and/or candesartan is safe and associated with excellent graft survival at 4 years: A single centre Australian experience

[20] Suppressive effects of type I angiotensin receptor antagonists, candesartan and irbesartan on allergic asthma

[21] Host-Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism

[22] Comparison of candesartan and angiotensin-(1-7) combination to mito-TEMPO treatment for normalizing blood pressure and sympathovagal balance in (mREN2)27 rats

[23] Candesartan inhibits inflammation through an angiotensin II type 1 receptor independent way in human embryonic kidney epithelial cells

[24] Effects of angiotensin II receptor blockade on cerebral, cardiovascular, counter-regulatory, and symptomatic responses during hypoglycaemia in patients with type 1 diabetes

[25] The effects of angiotensin II receptor antagonist (candesartan) on rat renal vascular resistance

[26] Internalization of Constitutively Active N111G Mutant of AT1 Receptor Induced by Angiotensin II–Receptor Antagonists Candesartan, Losartan, and Telmisartan: Comparison With Valsartan

[27] Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study

[28] Automated multi-step purification protocol for Angiotensin-I-Converting-Enzyme (ACE).

[29] [Association between both maternal and fetal angiotensinogen gene single nucleotide polymorphism and preeclampsia/eclampsia].

[30] Role of MicroRNAs in Renin-Angiotensin-Aldosterone System-Mediated Cardiovascular Inflammation and Remodeling

[31] An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.

[32] Investigations into mild electric foot shock stress-induced cognitive enhancement: possible role of angiotensin neuropeptides

[33] Association of seminal angiotensinogen with sperm motility and morphology in male infertility.

[34] Identification, structure-activity relationship and in silico molecular docking analyses of five novel angiotensin I-converting enzyme (ACE)-inhibitory peptides from stone fish (Actinopyga lecanora) hydrolysates.

[35] Angiotensin-converting enzyme gene polymorphism in arrhythmogenic right ventricular dysplasia: is DD genotype helpful in predicting syncope risk?

[36] Continuation of angiotensin converting enzyme inhibitors on the day of surgery is not associated with increased risk of hypotension upon induction of general anesthesia in elective non-cardiac surgeries

[37] Study of angiotensin converting enzyme (ACE) activity in patients with atherosclerosis and in healthy individuals.

[38] The new angiotensin II receptor blocker Edarbi® as part of the pathogenetic treatment of arterial hypertension in patients with metabolic disorders

[39] Simultaneous angiotensin receptor blockade and glucagon-like peptide-1 receptor activation ameliorate albuminuria in obese insulin-resistant rats.

[40] Brain Angiotensinergic Regulation of the Immune System: Implications for Cardiovascular and Neuroendocrine Responses.

[41] The Renin-Angiotensin System in the Central Nervous System and Its Role in Blood Pressure Regulation.

[42] Potentiation of Paclitaxel-Induced Pain Syndrome in Mice by Angiotensin I Converting Enzyme Inhibition and Involvement of Kinins.

[43] Angiotensin II receptor blockade reduces salt sensitivity of blood pressure through restoration of renal nitric oxide synthesis in patients with diabetic nephropathy

[44] Purification of fucoxanthin from Sargassum wightii Greville and understanding the inhibition of angiotensin 1-converting enzyme: An in vitro and in silico studies.

[45] Long-term clinical outcomes with use of an angiotensin-converting enzyme inhibitor early after heart transplantation.

[46] Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.

[47] Integration of Hypernatremia and Angiotensin II by the Organum Vasculosum of the Lamina Terminalis Regulates Thirst.

[48] The Other Angiotensin II Receptor: ATR as a Therapeutic Target.

[49] Downregulation of miR-96 suppresses the profibrogenic functions of cardiac fibroblasts induced by angiotensin II and attenuates atrial fibrosis by upregulating KLF13.

[50] Preparation of soy sauce by walnut meal fermentation: Composition, antioxidant properties, and angiotensin-converting enzyme inhibitory activities.

[51] A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).

[52] Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.

[53] COVID-19 and Renin Angiotensin Blockers: Current Evidence and Recommendations.

[54] Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers.

[55] Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

[56] Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword?

[57] Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension

[58] What Solid Organ Transplant Healthcare Providers should know about Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.

[59] Intravital Förster resonance energy transfer imaging reveals elevated [Ca2+]i and enhanced sympathetic tone in femoral arteries of angiotensin II-infused hypertensive biosensor mice

[60] Angiotensin Receptor Blockers and the Risk of Suicide: An Exercise in the Critical Examination of a Case-Control Study

[61] hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: a general practice-based, observational study.

[62] angiotensin-converting enzyme inhibitors-induced angioedema of the small bowel mimicking postoperative complication

[63] a study on the association between angiotensin-i converting enzyme i/d dimorphism and type-2 diabetes mellitus

[64] angiotensin-(1-7)/angiotensin-converting enzyme 2/mas receptor axis and related mechanisms

[65] new clinical investigations with selective angiotensin ii receptor blocker therapy in diabetes and renal disease

[66] circadian differences in the contribution of the brain renin-angiotensin system in genetically hypertensive mice

[67] ace inhibitors – angiotensin ii receptor antagonists: a useful combination therapy for ischemic heart disease

[68] normal-phase thin-layer chromatography of some angiotensin converting enzyme (ace) inhibitors and their metabolites

[69] angiotensin-(1–7) promotes resolution of eosinophilic inflammation in an experimental model of asthma

[70] peptides derived from rhopilema esculentum hydrolysate exhibit angiotensin converting enzyme (ace) inhibitory and antioxidant abilities

[71] angiotensin ii silencing alleviates erectile dysfunction through down-regulating the rhoa/rho kinase signaling pathway in rats with diabetes mellitus

[72] propiedades antioxidantes e inhibición de la enzima convertidora de angiotensina i (eca i) de fracciones ultrafiltradas de hidrolizados de hemoglobina bovina

[73] interplay of vitamin d, erythropoiesis, and the renin-angiotensin system

[74] when should we start using angiotensin converting enzyme inhibitors/angiotensin receptor blockers in diabetic kidney disease?

[75] o uso de inibidores da enzima conversora de angiotensina e sua relação com eventos no pós-operatório de cirurgia de revascularização miocárdica the use of inhibitors of angiotensin-converting enzyme and its relation to events in the postoperative period of cabg

[76] optimization of bromelain-aided production of angiotensin i-converting enzyme inhibitory hydrolysates from stone fish using response surface methodology

[77] influence of angiotensin ii subtype 2 receptor (at2r) antagonist, pd123319, on cardiovascular remodelling of aged spontaneously hypertensive rats during chronic angiotensin ii subtype 1 receptor (at1r) blockade

[78] association of angiotensin-converting enzyme gene dimorphisms with severity of lupus disease

[79] role of cardiac renin angiotensin system in ischemia reperfusion injury and preconditioning of heart

[80] angiotensin ii inhibitor facilitates epidermal wound regeneration in diabetic mice

[81] interactions between adenosine, angiotensin ii and nitric oxide on the afferent arteriole influence sensitivity of the tubuloglomerular feedback

[82] comparative study on angiotensin converting enzyme inhibitory activity of hydrolysate of meat protein of indonesian local livestocks

[83] cardiac-autonomic imbalance and baroreflex dysfunction in the renovascular angiotensin-dependent hypertensive mouse

[84] sulforaphane prevents angiotensin ii-induced testicular cell death via activation of nrf2

[85] the combination of beta blockers and renin-angiotensin system blockers improves survival in incident hemodialysis patients: a propensity-matched study

[86] rational drug design and synthesis of molecules targeting the angiotensin ii type 1 and type 2 receptors

[87] Southeast Asian medicinal plants with angiotensin converting enzyme (ACE) inhibition properties

[88] renin-angiotensin system antagonists, glomerular filtration rate and blood pressure

[89] effect of renin-angiotensin system blockage in patients with acute respiratory distress syndrome: a retrospective case control study

[90] standardization of a fluorimetric assay for the determination of tissue angiotensin-converting enzyme activity in rats

[91] angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease – demystifying controversies

[92] kinin b1 receptor antagonism is equally efficient as angiotensin receptor 1 antagonism in reducing renal fibrosis in experimental obstructive nephropathy, but is not additive.

[93] angiotensin receptor blocker add-on therapy in portal hypertension: to use angiotensin receptor blocker or not to use, that is the question

[94] delayed angioedema during therapy with angiotensin-converting enzyme inhibitors

[95] combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model

[96] angiotensin ii receptor blockers in the prevention of complications from atrial fibrillation

[97] the role of genetic polymorphisms of the renin–angiotensin system in renal diseases: a meta-analysis

[98] anti-inflammatory and antitumor effects of hydroxytyrosol but not oleuropein on experimental glioma in vivo. a putative role for the renin-angiotensin system

[99] an angiotensin i converting enzyme polymorphism is associated with clinical phenotype when using differentiation-syndrome to categorize korean bronchial asthma patients

[100] examination of the lipid profile in pregnant obese women, considering the allele status of the genes of angiotensin-converting enzyme (ace i / d) and plasminogen-1 (pa-1 4g / 5g) activator-inhibitor

[101] nitric oxide regulates angiotensin-i converting enzyme under static conditions but not under shear stress